Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, including its biobank of customer genetic samples, have been purchased by American biotechnology company Regeneron Pharmaceuticals for a cool $256 million, the highest bid submitted in the once-hot startup’s bankruptcy auction.

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal genetic data. What to know

But, more concerning than the success or failure of a particular company, was this question: What would happen to 23andMe's vast trove of highly personal customer data? We aren't just talking about usernames and birthdays.